23.03.2023
Ashurst article on AI & Automation in Biotech with great assessment
Pharma R&D is facing a continuous decline in productivity with exploding development costs, year after year. This evolution is only made worse with the onset of novel, more complex bio-therapeutics aimed at fighting complex diseases such as cancer. And this is despite the much discussed technological advancements in AI-based drug discovery. Players in Biotech all suffer from the same problem: Today, no useful data sets are in existence to efficiently train AI on the multi-dimensional challenges posed by the development of multi-targeting antibodies.
A key problem hereby lies in the inefficiency of current discovery processes, as most biological research is still conducted manually and in a “one factor at a time“-manner. As it has always been through the past decades.
We are now entering the era of platform technologies with data being the currency of the 21st century. Perspix believes, that not in isolation, but the integration of lab-based experimentation with new technologies such as AI and automation into an E2E platform will provide novel options and promise to boost the chance to make it into the clinic – efficiently and reliably.
See Ashurst’s article making a great point…
01.03.2023
Perspix Biotech attended annual European Life Sciences CEO Forum
On 1st and 2nd March 2023, Perspix Biotech attended the 16th European Life Sciences CEO Forum by Sachs Associates in Zurich.
Perspix was featured among the “Rising Biotech Stars” and presented its platform technology to potential partners and investors. The forum also comprised a series of panels and presentations from leading pharmaceutical, biotech and investment companies, accompanied by expert outlooks on growth and investment activities.
Perspix used this opportunity to connect with investors, agencies, and industry partners, and increase its visibility in Europe’s Biotech industry.
08.02.2023
Matthias Wiedenfels appointed CEO of Perspix, José Airas rotating to his new role as COO
It is our pleasure to announce the transitions of Matthias Wiedenfels and of José Airas into new roles at Perspix Biotech. Matthias served in the company as Chairman of the Board since 2021 and is moving into an active role as CEO of Perspix Biotech. Together with the leadership team, Matthias will be at the steering wheel of the company. He will take over the responsibility for Corporate Strategy and Governance, and he will manage all activities around Investor Relations.
Matthias has more than 20 years of industrial experience and brings a lot of operational know-how to his new role as former CEO of STADA Group. His is a renowned expert in healthcare and corporate finance and holds a Doctor of Laws degree. In his new and exposed leadership role and with his experience as active investor and serial entrepreneur in healthcare and technology ventures, Matthias will be of central value for advancing Perspix to the next level.
With Matthias moving into the role of CEO of Perspix, José will focus on his overall Corporate Responsibilities and on leading our Business Strategy and Operations as newly established COO of Perspix. José is a co-founder of Perspix and focuses on driving our Corporate Strategy as CEO since.
Please join us in welcoming both, Matthias and José, in their new roles. With the support of our Board Members, this enriched leadership team will be the key driver towards Perspix’s vision.
09.04.2022
Jörg Birkenfeld appointed as Scientific Director
Perspix Biotech announces the appointment of Dr. Joerg Birkenfeld to the position of Scientific Director. In this role, Joerg will be responsible for overseeing and coordinating all technology development aspects as well as leading research teams with the goal of creating a first-in-class pipeline of multi-targeting biopharmaceuticals for hematologic and solid tumors.
Joerg holds a Ph.D. in biochemistry from Goethe University and Max Planck Institute for Brain Research (both Frankfurt, Germany) and was a postdoctoral fellow in immunology at Scripps Research Institute (La Jolla, USA). He joins Perspix from Sanofi Aventis Deutschland GmbH where, as head of high-throughput biologics, he was responsible for the development of an automated value chain for large molecule engineering. Prior to that, he served as the lead for therapeutic antibody optimization at Bayer Healthcare in the Global Biologics division. In both positions, he led the optimization of biotherapeutical drug candidates and their transition to technical development. Joerg has authored numerous scientific articles and granted patents or patent applications, including several related to the optimization of mono- and multi-specific antibodies.
“I am extremely happy to welcome Joerg to the company as Scientific Director and I am very excited to work with him in the Executive Leadership Team” said Dr. José Airas, CEO of Perspix Biotech. “Joerg is an acknowledged scientific leader with long standing expertise in biopharmaceutical R&D. Especially his knowledge and background in the fields of lab automation and data-driven antibody engineering will be pivotal for Perspix to reach its goal of becoming a leader in the area of next-generation biotherapeutical discovery and development.“
“I am really thrilled to join Perspix” says Joerg. “The job perfectly aligns with my experience in industry, and it provides a unique opportunity to realize my vison of future drug discovery. I am convinced that Perspix’s holistic digital approach will revolutionize drug development and will create most innovative medicines at unmatched efficiency. I am proud to become part of this important endeavor.”
Dr. Matthias Wiedenfels, Perspix’s Chairman of the Advisory Board, commented “Having visionary people with transformative knowledge on board is absolutely essential at our early company stage. Joerg brings a unique set of skills to Perspix combining wide-ranging expertise in biotherapeutical drug discovery with broad knowledge in the field of digital transformation of R&D processes. I am absolutely delighted to see Joerg joining and filling this key role as Scientific Director at this very significant time for Perspix.”
10.01.2022
Prof. Hartmut Michel and Dr. Tomás Tomeo Foncuberta joining Perspix’s Advisory Board
2021 was a special year for Perspix Biotech, as the founding year is for any company. We are very proud of our first steps in corporate development, fundraising, strategizing, and team building.
Regarding the latter, we are immensely honored to announce the next additions to our Board of Advisors. With the start of the new year, we hearty welcome Prof. Dr. Dr. hc mult Hartmut Michel and Dr. Tomás Tomeo Foncuberta to our advisory team:
- It would take too long to list all titles, memberships, and awards of Prof. Hartmut Michel, his most prestigious being the 1988 Nobel Prize in Chemistry. Prof. Michel received a PhD in Biochemistry from the University of Wuerzburg in 1977 and dedicated his whole career to the study of protein structure to reveal the fundamentals of their function. Since 1987, Prof. Michel has been director at the Max Planck Institute of Biophysics and since 1989 adjunct professor of biochemistry at the Goethe University, both located in Frankfurt am Main, Germany.
Beside his vast academic accomplishments, Prof. Michel has acted as scientific advisor for major pharma and biotech companies and as investment consultant for corporate investors.
Building on his invaluable expertise, we are very much looking forward to working with Prof. Michel to shape Perspix Biotech’s strategy towards establishing a world-class portfolio of next-generation biotherapeutics.
Beside his vast academic accomplishments, Prof. Michel has acted as scientific advisor for major pharma and biotech companies and as investment consultant for corporate investors.
Building on his invaluable expertise, we are very much looking forward to working with Prof. Michel to shape Perspix Biotech’s strategy towards establishing a world-class portfolio of next-generation biotherapeutics.
- Among other academic titles, Dr. Tomeo Foncuberta holds a doctor degree in Economics and received an MBA from the ESADE Business School. He went on to extend his Executive Education at the Harvard Business School, and later certified in fundraising at the Indiana University.
In 2004, Dr. Tomeo Foncuberta entered the IESE Business School (Top1 Executive Education, Financial Times ranking). As Associate Dean he oversees the school’s Corporate Development and Fundraising and serves as director of educational programs including Executive Education and Executive MBA.
With his extensive entrepreneurial experience, Dr. Tomeo Foncuberta will play a critical role at Perspix ensuring an efficient and sustainable company setup and growth, advising the team in all aspects around Corporate Development.
Please join us welcoming both distinguished professionals to our company’s board.
08.10.2021
Matthias Wiedenfels to join Perspix at Chairman of the Board
It is our honor to announce Matthias Wiedenfels as Chairman of the Board at Perspix Biotech. Matthias is an integral member since the initiation of the company and was crucial in defining the company’s goals and mission. He will now play a leading role in taking Perspix to the next level
Matthias is an expert in healthcare and corporate finance with more than 20 years of industrial experience. He received an academic training A.L. University in Freiburg and holds a Doctor of Laws degree. Matthias held various positions in multinational pharma companies, most notably as the former CEO of STADA Pharmaceutical AG. Today, he is an active investor and serial entrepreneur in healthcare and technology ventures, he likes strategic and operative challenges.
Matthias, we are glad to have your expertise on board as we advance towards our vision of making tailored Next-Gen biotherapeutics a reality, an affordable reality.
Matthias, welcome to the team 🙏🏼
24.09.2021
Perspix moves into the FIZ Frankfurt Innovation Center for Biotechnology
We are very pleased to announce the move of Perspix Biotech into the campus of the FiZ Frankfurt Biotechnology Innovation Center (www.fiz-biotech.de). We are very excited about this opportunity and are highly motivated to make use of all the virtues that come along with this shift. The innovation hub provides our young company not only room to implement its strategy but also the necessary chance to grow its vision.
The FiZ offers its small- and medium-sized life science companies a great and state of the art infrastructure. Importantly, it also provides access to collaborations and interdisciplinary networks and it initiates and manages FiZ Synergy Projects. It is located within the Frankfurt Biocenter and is in close vicinity to the Max Planck Institutes for Brain Research and for Biophysics and to other academic research institutions.
Our team is looking forward to welcoming you at the FiZ…
Now it is time for change
Copyright 2022 Perspix Biotech | All rights reserved
Copyright 2022 Perspix Biotech | All rights reserved